MoonLake Immunotherapeutics Income Statement (2020-2026) | MLTX

Income Statement Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Operating items
Research & Development (Quarter)
29.87M0.67M35.53M10.45M11.40M9.02M11.37M7.42M8.70M7.59M8.10M13.01M23.66M35.74M40.36M36.46M49.76M60.63M56.01M54.52M
Selling, General & Administrative (Quarter)
2.81M5.60M18.05M5.49M6.25M5.75M5.33M5.52M4.48M5.39M6.93M6.81M6.92M7.38M9.22M11.03M10.94M10.80M9.21M15.51M
Operating Expenses (Quarter)
32.68M6.27M53.58M15.94M17.65M14.77M16.70M12.93M13.19M12.98M15.03M19.82M30.58M43.11M49.58M47.48M60.70M71.43M65.22M70.02M
Operating Income (Quarter)
-32.68M-6.27M-53.58M-15.94M-17.65M-14.77M-16.70M-12.93M-13.19M-12.98M-15.03M-19.82M-30.58M-43.11M-49.58M-47.48M-60.70M-71.43M-65.22M-70.02M
EBIT (Quarter)
-32.68M-6.27M-53.58M-15.94M-17.65M-14.77M-16.70M-12.93M-13.19M-12.98M-15.03M-19.82M-30.58M-43.11M-49.58M-47.48M-60.70M-71.43M-65.22M-70.02M
Non-operating items
Interest & Investment Income (Quarter)
0.01M0.00M0.00M0.01M
Other Non Operating Income (Quarter)
-0.00M-0.02M-0.06M0.07M0.25M0.04M0.24M0.72M0.84M1.39M7.19M5.92M5.90M7.09M3.23M7.10M6.78M4.05M4.44M3.21M
Non Operating Income (Quarter)
-0.00M-0.02M-0.06M0.07M0.25M0.04M0.24M0.72M0.84M1.39M
Net income details
EBT (Quarter)
-32.69M-6.29M-53.64M-15.87M-17.41M-14.73M-16.46M-12.21M-12.34M-11.59M-7.84M-13.90M-24.68M-36.02M-46.35M-40.41M-55.96M-70.58M-62.77M-69.08M
Tax Provisions (Quarter)
0.00M0.01M0.01M0.01M0.01M0.01M0.01M0.03M0.04M0.07M0.08M0.09M0.04M0.15M0.10M0.12M0.25M0.62M
Profit After Tax (Quarter)
-32.69M-6.29M-53.64M-15.88M-17.42M-14.74M-17.11M-12.22M-12.35M-9.43M-7.44M-13.97M-24.76M-36.11M-45.60M-40.56M-56.05M-70.69M-65.43M-69.71M
Income from Non-Controlling Interests (Quarter)
-5.30M-4.58M0.59M-3.21M-2.30M-2.19M-1.00M-0.30M-0.48M-0.72M-0.75M-0.61M-0.83M-0.97M-0.59M
Income from Continuing Operations (Quarter)
-32.69M-6.29M-53.64M-15.88M-17.42M-14.74M-16.47M-12.22M-12.35M-11.62M-7.89M-13.97M-24.76M-36.11M-46.40M-40.56M-56.05M-70.69M-63.02M-69.71M
Consolidated Net Income (Quarter)
-32.69M-6.29M-53.64M-15.88M-17.42M-14.74M-16.47M-12.22M-12.35M-11.62M-7.89M-13.97M-24.76M-36.11M-46.40M-40.56M-56.05M-70.69M-63.02M-69.71M
Income towards Parent Company (Quarter)
-32.69M-6.29M-53.64M-15.88M-17.42M-14.74M-16.47M-12.22M-12.35M-11.62M-7.89M-13.97M-24.76M-36.11M-46.40M-40.56M-56.05M-70.69M-63.02M-69.71M
Net Income towards Common Stockholders (Quarter)
-32.69M-6.29M-53.64M-15.88M-17.42M-14.74M-16.47M-12.22M-12.35M-11.62M-7.89M-13.97M-24.76M-36.11M-46.40M-40.56M-56.05M-70.69M-63.02M-69.71M
Additional items
EPS (Basic) (Quarter)
-2.11-2.63-6.84-3.17-0.34-0.27-0.43-0.23-0.23-0.18-0.10-0.22-0.39-0.56-0.72-0.63-0.87-1.10-0.92-0.98
EPS (Weighted Average and Diluted) (Quarter)
-2.90-2.63-6.84-3.17-0.34-0.27-0.43-0.23-0.23-0.18-0.10-0.22-0.39-0.56-0.72-0.63-0.87-1.10-0.92-0.98
Shares Outstanding (Weighted Average) (Quarter)
15.63M9.69M7.84M5.01M35.20M36.93M29.36M39.06M41.40M45.49M49.12M62.64M62.87M62.90M62.87M63.23M63.28M63.30M64.46M71.27M
Shares Outstanding (Diluted Average) (Quarter)
15.63M9.69M7.84M5.01M20.19M36.93M29.36M39.06M43.72M53.52M49.12M62.64M62.76M62.80M62.87M63.23M63.26M63.37M64.46M71.27M
EBITDA (Quarter)
-32.69M-6.29M-53.81M-15.61M-17.31M-10.00M-16.93M-9.02M-10.49M-8.14M-8.42M-13.71M-23.70M-36.55M-44.19M-43.22M-57.95M-70.94M-62.70M-69.99M
Interest Expenses (Quarter)
657.000.02M2.04M3.20M1.99M2.27M
Tax Rate (Quarter)
-0.01%-0.05%-0.05%-0.06%-0.07%-0.09%-0.08%-0.25%-0.56%-0.50%-0.32%-0.26%-0.09%-0.38%-0.17%-0.16%-0.40%-0.90%